http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103479653-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_653c418e41edbb4e1ce8bc5e53e70cec |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 |
| filingDate | 2013-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df6f0fb4aa54d46486e8852f588485a6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93683ae9d72a95385de56ab13f91ef80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4f62d2ae332af5c63aedb33739ec1bb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79a758f651c565705a60b84d753650e3 |
| publicationDate | 2014-01-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103479653-A |
| titleOfInvention | Aspirin-esomeprazole compound enteric-coated pellet preparation and preparation method |
| abstract | The invention relates to an aspirin-esomeprazole compound enteric-coated pellet preparation and a preparation method thereof. The ratio is 3-6:1. There are two types of compound enteric-coated pellets. One is aspirin pellets as the drug-containing pellet core, which is successively covered with isolation layer I, esomeprazole magnesium drug layer, isolation layer II, and enteric coating layer; The second is to prepare aspirin enteric-coated pellets and esomeprazole enteric-coated pellets respectively, and then mix them to obtain compound enteric-coated pellets. The invention has the advantages that the drug is released in the intestinal tract, avoiding the destruction of the acidic environment of the drug in the stomach; the compound preparation antagonizes the side effect of aspirin on gastrointestinal stimulation, so as to facilitate the long-term use of aspirin and exert its effect of inhibiting platelet aggregation; The pill form releases the drug, which has high bioavailability, less fluctuation of blood drug concentration, and lower side effects. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112190564-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107224585-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110478333-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111939139-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107224585-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110538165-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110538165-A |
| priorityDate | 2013-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.